Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.7K
1.7K
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

129
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
129
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.3K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.3K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

94
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies.

Medicine·2024
Same author

Huisarts en wetenschap·2021
Same author

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.

BMC cardiovascular disorders·2019
Same author

The association of plasma fatty acids with hand and knee osteoarthritis: the NEO study.

Osteoarthritis and cartilage·2019
Same author

Avoiding selection bias in metabolomics studies: a tutorial.

Metabolomics : Official journal of the Metabolomic Society·2019
Same author

Interrelationship of the rs7903146 TCF7L2 gene variant with measures of glucose metabolism and adiposity: The NEO study.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2017
Same journal

[Insulin intoxications caused by falsified semaglutide].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[Professional skepticism in medical research].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[Improving mobility in painful osteoarthritis].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[The effectiveness and costs of the Back At work After Surgery (BAAS) work-integrated care pathway on return to work for patients receiving knee arthroplasty].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[The rise of genetic therapies: urgent moral and societal questions].

Nederlands tijdschrift voor geneeskunde·2026
Same journal

[A man with a wound on his elbow].

Nederlands tijdschrift voor geneeskunde·2026
See all related articles

Related Experiment Video

Updated: Mar 17, 2026

Molecular Evolution of the Tre Recombinase
12:02

Molecular Evolution of the Tre Recombinase

Published on: May 29, 2008

10.1K

[Personalized medicine: evolution or revolution?].

O M Dekkers1, D O Mook-Kanamori, F R Rosendaal

  • 1LUMC, afd. Klinische Epidemiologie, Leiden.

Nederlands Tijdschrift Voor Geneeskunde
|July 21, 2016
PubMed
Summary
This summary is machine-generated.

Personalized medicine integrates genetic data with clinical information for tailored treatments. However, current evidence shows limited improvement in prognosis or clinical outcomes for most conditions.

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.3K
Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine
06:14

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine

Published on: September 19, 2025

1.1K

Related Experiment Videos

Last Updated: Mar 17, 2026

Molecular Evolution of the Tre Recombinase
12:02

Molecular Evolution of the Tre Recombinase

Published on: May 29, 2008

10.1K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.3K
Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine
06:14

Automating Tumor Implantation in Zebrafish Larvae for Cancer Research and Medicine

Published on: September 19, 2025

1.1K

Area of Science:

  • Genomics
  • Clinical Medicine
  • Translational Science

Background:

  • Personalized medicine leverages individual patient data for tailored prognosis and therapy.
  • The integration of genetic and molecular information into clinical care is a key goal.
  • Existing clinical data is routinely collected for patient management.

Purpose of the Study:

  • To evaluate the impact of incorporating genetic and molecular data into clinical care.
  • To assess whether personalized medicine approaches improve prognostic accuracy.
  • To determine if genetic or molecular knowledge enhances therapeutic decision-making and clinical outcomes.

Main Methods:

  • Review of current personalized medicine strategies.
  • Analysis of studies integrating genetic/molecular data with clinical data.
  • Assessment of prognostic improvements in various clinical conditions.
  • Evaluation of clinical outcome data based on genetically guided therapies.

Main Results:

  • Additional genetic and molecular information has not consistently improved prognostic ability across many conditions.
  • Therapeutic decisions guided by genetic or molecular knowledge have not demonstrated improved clinical outcomes for most diseases.
  • The added value of personalized medicine in enhancing patient prognosis and treatment efficacy remains limited in current practice.

Conclusions:

  • The clinical utility of personalized medicine, particularly regarding improved prognosis and outcomes, requires further validation.
  • Current integration of genetic and molecular data has not yet translated into significant clinical benefits for the majority of conditions.
  • Future research should focus on identifying specific scenarios and biomarkers where personalized medicine demonstrably improves patient care.